Daily Sepsis Research Analysis

High-performance protein point-of-care testing (POCT) has become a critical clinical need, particularly for rapid decision-making in acute settings. However, current protein POCT technologies, such as lateral flow assays and electrochemical sensors, struggle to simultaneously achieve high sensitivity, operational simplicity, and robustness. In this work, an integrated digital microfluidic platform for multiplexed luminescence oxygen channeling immunoassay (iDMF-mLOCI) is developed, leveraging precise droplet manipulation on DMF to create a wash-free, multiplexed suspension assay for protein POCT. This system uniquely features: (1) Fast on-chip plasma separation (<30 s); (2) No washing cycles (100% bead retention, 23% faster processing versus conventional DMF immunoassays) and (3) High reproducibility (coefficient of variations (CVs) < 9.1%). These advancements enable sensitive multiplexed detection of protein biomarkers (Limits of detection (LODs): 2.2 pg/mL for interleukin-6 (IL-6), 0.05 ng/mL for procalcitonin (PCT), 0.2 ng/mL for heparin-binding protein (HBP)) using only 2.2 μL of trace sample per test. Utilizing the established iDMF-mLOCI platform, diagnostic capability for sepsis is assessed, which demonstrates excellent diagnostic accuracy (area under curve (AUC) = 0.934) and strong correlation with clinical widely used central laboratory testing methods (coefficient of determination (R

INTRODUCTION: This study aimed to evaluate the association between magnesium sulfate and mortality in patients with Sepsis-Associated Encephalopathy (SAE), given the lack of established therapies and emerging evidence of magnesium's neuroprotective properties. METHODS: A retrospective cohort study was conducted using data from SAE patients in the MIMICIV database. Patients were stratified into magnesium sulfate-treated and non-treated groups, with 1:1 Propensity Score Matching (PSM) to adjust for baseline imbalances. Outcomes included 28-day all-cause mortality, in-hospital mortality, and Intensive Care Unit (ICU)/hospital Length of Stay (LOS). Cox regression, Kaplan-Meier analysis, and subgroup assessments were performed. RESULTS: A total of 12,296 patients with SAE who met the inclusion and exclusion criteria participated in this study. Before PSM, magnesium sulfate administration correlated with a 36% reduction in 28-day mortality (17.11% vs. 23.77%; Hazard Ratio [HR] 0.64, 95% CI 0.58-0.70) and a 43% decrease in in-hospital mortality (14.32% vs. 18.23%; HR 0.57, 95% CI 0.51-0.63) (both p < 0.001). Post-PSM analysis of 7,236 matched patients confirmed consistent benefits (28-day mortality HR 0.66; in-hospital mortality HR 0.62). However, patients treated with magnesium sulfate had longer median ICU LOS (3.87 vs. 2.64 days; p < 0.001) and hospital LOS (10.12 vs. 8.70 days; p < 0.001). Subgroup analyses demonstrated robustness across demographics and comorbidities. DISCUSSION: The significant association between magnesium sulfate and reduced mortality in SAE patients suggests its potential neuroprotective role, possibly mediated through mechanisms such as blood-brain barrier stabilization, anti-inflammatory effects, and N-methyl-D-aspartate (NMDA) receptor antagonism. The observed prolongation of ICU and hospital stay may reflect survivor bias and the necessary time for neurological recovery in these critically ill patients, rather than a direct adverse effect of the therapy. These findings position magnesium sulfate as a promising adjunctive therapy for SAE, warranting a paradigm shift in its consideration for neuroprotection in sepsis. CONCLUSION: This large-scale retrospective study found that magnesium sulfate administration was associated with reduced 28-day and in-hospital mortality in SAE patients, alongside prolonged length of hospital and ICU stay. These findings highlight magnesium sulfate's potential as an adjunctive SAE therapy, though multicenter randomized trials are warranted to validate this association and optimize dosing protocols.

BACKGROUND: Sepsis is a medical emergency associated with high morbidity and mortality rates. Rapid pathogen identification and early antimicrobial susceptibility results are essential for optimizing treatment. Conventional protocols require at least 24 h, delaying clinical decision-making. This study evaluated the accuracy and feasibility of a short-incubation protocol compared to the traditional method. METHODS: This diagnostic accuracy study included positive monomicrobial blood cultures from patients across all age groups. The index test used biomass collected after a 6-h incubation on solid media, whereas the reference standard employed the conventional 24-h protocol. Outcomes assessed were agreement in bacterial identification by MALDI-TOF MS, detection of resistance mechanisms, and categorical agreement in antimicrobial susceptibility profiles (AST) using the VITEK® 2 XL system. Diagnostic performance was determined by overall agreement, Cohen's kappa (κ), sensitivity, and predictive values. RESULTS: 154 monomicrobial blood cultures were analyzed. For bacterial identification, the short-incubation protocol demonstrated overall agreement (κ = 0.99; 95% CI: 0.96-1.00), with only one discordant result. For AST, overall agreement reached 96.5% (κ = 0.91). While the highest concordance was observed for common Enterobacterales such as Escherichia coli and Klebsiella pneumoniae, discrepancies were noted for specific drug-organism pairs, particularly among Gram-positive cocci and for certain beta-lactams. CONCLUSIONS: The 6-h short-incubation protocol represents a robust alternative for rapid pathogen identification via MALDI-TOF MS, reducing diagnostic turnaround time by up to 18 h. However, the observed variability in AST for critical combinations suggests that clinical implementation must be stratified and selective, prioritizing patient safety over reporting speed.